[ad_1]
Investing.com – Biomarin Pharma (NASDAQ:) reported on Wednesday third quarter that beat analysts’ forecasts and income that fell wanting expectations.
Biomarin Pharma introduced earnings per share of $-0.2 on income of $408.7M. Analysts polled by Investing.com anticipated EPS of $-0.2427 on income of $435.89M.
Biomarin Pharma shares are down 18.21% from the start of the yr and are buying and selling at $71.50 , down-from-52-week-high.They’re under-performing the which is up 18.21% yr thus far.
Biomarin Pharma shares misplaced 0.31% in after-hours commerce the report.
Biomarin Pharma follows different main Healthcare sector earnings this month
Biomarin Pharma’s report follows an earnings beat by J&J on Tuesday, October 19, 2021, who reported EPS of $2.6 on income of $23.34B, in comparison with forecasts EPS of $2.35 on income of $23.64B.
Thermo Fisher Scientific had beat expectations on Wednesday with third quarter EPS of $5.76 on income of $9.33B, in comparison with forecast for EPS of $4.68 on income of $8.33B.
Keep up-to-date on the entire upcoming earnings reviews by visiting Investing.com’s earnings calendar
[ad_2]
Source link
